Back to Hematology
Hematologyv2018Evidence-Based

GIPSS - Genetically Inspired Prognostic Scoring System for Primary Myelofibrosis

The GIPSS is a genetically-based prognostic scoring system for primary myelofibrosis that relies exclusively on cytogenetic and molecular genetic markers. This system eliminates subjective clinical variables and provides more accurate risk stratification for treatment planning, particularly for allogeneic stem cell transplant decisions.

Clinical Input Parameters

Clinical Assessment
Awaiting Parameters
gipss score
—points
Ready to Calculate

Awaiting Clinical Input

Enter the clinical input parameters on the left and click Run Clinical Assessment to evaluate this medical calculator with deterministic clinical scoring.

Open in Web App
Clinical decision support tool for licensed medical practitioners. Confirm independently before prescribing or clinical action.

When & Why to Use

The GIPSS - Genetically Inspired Prognostic Scoring System for Primary Myelofibrosis is utilized in clinical practice for risk stratification, diagnostic probability estimation, and treatment decision-making within hematology.

Use this tool during initial patient intake, emergency department workup, or bedside assessment when objective clinical scoring is required to guide management or admission decisions.

Clinical Formula & Scoring Logic

GIPSS Score = Karyotype Risk Points + CALR Type 1 Absence Points + ASXL1 Mutation Points + SRSF2 Mutation Points + U2AF1Q157 Mutation Points, where total score ranges from 0-6 points

Clinical Pearls & Practice Notes

  • GIPSS is based exclusively on genetic markers: mutations and karyotype
  • This system eliminates subjective clinical variables used in other scoring systems
  • Can be performed on peripheral blood samples, avoiding bone marrow aspiration challenges
  • Particularly valuable for patients with fibrotic marrows where bone marrow sampling is difficult
  • Designed specifically for primary myelofibrosis but may apply to secondary myelofibrosis
  • Superior to DIPSS (Dynamic International Prognostic Scoring System) in cases of disagreement
  • Primary utility is in identifying candidates for allogeneic stem cell transplant (high-risk)
  • Low-risk patients may be managed with observation and minimal intervention
  • Should be interpreted in conjunction with patient age, comorbidities, and transplant eligibility
  • Regular reassessment may be needed as additional genetic markers are discovered

Evidence & Literature Citations

  1. Tefferi A, Guglielmelli P, Nicolosi M, et al. GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis. Leukemia. 2018;32(7):1631-1642. doi: 10.1038/s41375-018-0107-z.
  2. Passamonti F, Giorgino T, Mora B, et al. A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis. Leukemia. 2017;31(12):2726-2731. doi: 10.1038/leu.2017.169.
  3. Guglielmelli P, Lasho TL, Rotunno G, et al. MIPSS70: Mutation-Enhanced International Prognostic Score System for transplantation-age patients with primary myelofibrosis. J Clin Oncol. 2018;36(4):310-318. doi: 10.1200/JCO.2017.76.4886.

Score Interpretation Ranges

Low Risk0 – 0 pts

Excellent prognosis

Intermediate-1 Risk1 – 1 pts

Good prognosis

Intermediate-2 Risk2 – 2 pts

Intermediate prognosis

High Risk3 – 6 pts

Poor prognosis

Need Clinical Suite Access?

Run this calculator with patient history, laboratory integration, and drug interaction safety checks on the DexaMed clinician app.

Open in Web App

Clinical Decision Support (CDS) Notice & Legal Disclaimer

This medical calculator and its scoring interpretation are provided strictly for licensed healthcare professionals and medical trainees as an educational and clinical decision support instrument. It does not replace independent clinical judgment, comprehensive patient history, physical examination, or attending physician oversight. Not FDA-cleared as an autonomous diagnostic medical device. Read the full DexaMed Medical Disclaimer.